# Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

Source: https://onco.cc/trials/nct07410494/  
OnCo record `nct07410494` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial in pancreatic cancer, run by Essen Biotech, now recruiting.

## Summary

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors is a phase 1/2, interventional study registered as NCT07410494 by Essen Biotech, with a registry enrolment figure of 85 participants, started 2026-02-01 and due to reach its primary completion in 2027-12-28. Interventions recorded: EB-SELECT Single-Target CAR-NK Cells; Dual-Target Antigen-Selected CAR-NK. Conditions listed: Cancer; Breast Cancer; Non-Small Cell Lung Cancer (NSCLC); Colorectal Cancer (Locally Advanced or Metastatic); Prostate Cancer - Recurrent; Pancreatic Ductal Adenocarcinoma (PDAC); Ovarian Cancer; Glioblastoma; Melanoma (Skin Cancer); Acute Myeloid Leukemia (AML); Non Hodgkin Lymphoma; Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma; Liver Cancer. Primary outcome: Incidence, type, and severity of adverse events (AEs), graded by CTCAE v5.0; Incidence of Dose-Limiting Toxicities (DLTs). Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: SELECT-CAR-NK
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07410494
- Phase: 1/2
- Setting: A Phase 1/2, Open-Label, Biomarker-Driven Study of Allogeneic Donor-Derived CAR-NK Cells With Antigen Selection by Tissue Biopsy and/or Liquid Biopsy Profiling in Participants With Relapsed/Refractory Advanced Solid Tumors (Single-Target vs Dual-Target Strategy)
- Sponsor: Essen Biotech
- Enrolled: 85

## Sources

- ClinicalTrials.gov NCT07410494: https://clinicaltrials.gov/study/NCT07410494

## Connected records

- cancers: [Locally advanced unresectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/locally-advanced-pdac/), [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07410494.json